Medifast, Inc. cash flow to debt ratio of 40.89% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Medifast, Inc.'s free cash flow has decreased -92.66% from $17.02M last year to $1.25M, signaling decreasing performance

Medifast, Inc.'s debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Medifast, Inc.'s debt has increased relative to shareholder equity from 0.08 last year to 0.08 today, signaling weakened financials

Medifast, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Medifast, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Medifast, Inc.'s profit margin has decreased (-1.77K%) in the last year from 0.35% to -5.79%, signaling decreasing performance

Medifast, Inc.'s short-term assets of $201.68M exceed its short-term liabilities of $42.96M

Medifast, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Medifast, Inc.'s return on equity of -9.68%, is lower than 15.00%, indicating bad performance

Medifast, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Medifast, Inc. had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings

Medifast, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Medifast, Inc. has a free cash flow yield of 1.07%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Medifast, Inc.'s yearly earnings has decreased -992.97% since last year from $2.09M to $-18.67M, signaling decreasing performance

Medifast, Inc.'s yearly revenue has decreased -35.96% since last year from $602.46M to $385.79M, signaling decreasing performance

ROIC -6.57% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Medifast, Inc.'s 3-year revenue CAGR of -37.74% is negative, indicating declining revenue over the past 3 years

Medifast, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Medifast, Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity

Medifast, Inc. is overvalued relative to its fair value price of 6.65 based on Discounted Cash Flow model

Medifast, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Medifast, Inc. is overvalued relative to its fair value price of 4.22 based on EBITDA multiple model

Medifast, Inc. has an EV/EBITDA ratio of 9.69x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Medifast, Inc. is undervalued relative to its fair value price of 26.35 based on Earnings Fair Value model

Medifast, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Medifast, Inc. has a price-to-book ratio of 0.59x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Medifast, Inc. has a price-to-sales ratio of 0.34x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue